1. Home
  2. HRMY vs HSAI Comparison

HRMY vs HSAI Comparison

Compare HRMY & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$41.14

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Hesai Group each ADS represents one Class B ordinary share

HSAI

Hesai Group each ADS represents one Class B ordinary share

HOLD

Current Price

$16.27

Market Cap

2.7B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
HSAI
Founded
2017
2014
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.7B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
HRMY
HSAI
Price
$41.14
$16.27
Analyst Decision
Buy
Strong Buy
Analyst Count
9
4
Target Price
★ $44.11
$31.58
AVG Volume (30 Days)
849.5K
★ 1.2M
Earning Date
05-07-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 7.97
N/A
EPS
★ 1.84
N/A
Revenue
★ $868,453,000.00
N/A
Revenue This Year
$19.75
$46.29
Revenue Next Year
$12.88
$41.32
P/E Ratio
★ $22.37
$61.18
Revenue Growth
★ 21.51
N/A
52 Week Low
$25.52
$14.29
52 Week High
$43.49
$29.35

Technical Indicators

Market Signals
Indicator
HRMY
HSAI
Relative Strength Index (RSI) 52.86 42.61
Support Level $40.92 $15.81
Resistance Level $43.38 $19.29
Average True Range (ATR) 1.21 0.51
MACD -0.27 -0.12
Stochastic Oscillator 40.51 8.69

Price Performance

Historical Comparison
HRMY
HSAI

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About HSAI Hesai Group each ADS represents one Class B ordinary share

Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.

Share on Social Networks: